









Markets
/
Stocks
/
nasdaq-aplt
/

Applied Therapeutics Inc

APLT

0.103USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

14.86MMarket Cap

LossP/E TTM



Applied Therapeutics Inc

0.103

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Applied Therapeutics Inc

Currency: USD Updated: 2026-02-02

Key Insights

Applied Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 174 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 0.25.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Applied Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

174 / 393

Overall Ranking

306 / 4529

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Applied Therapeutics Inc Highlights

StrengthsRisks

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).

Growing

The company is in a growing phase, with the latest annual income totaling USD 455.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 455.00K.

Overvalued

The company’s latest PE is -1.03, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 97.84M shares, increasing 0.04% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 6.35M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.73.

Analyst Rating

Based on 0 analysts

Current Rating

0.250

Target Price

+142.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-02

Its latest quarterly revenue reached 1.00M, representing a year-over-year increase of 719.67%, while its net profit experienced a year-over-year increase of 72.31%.

Score

Industry at a Glance

Previous score

7.08

Change



Financials

6.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.10

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.49

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Applied Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-02

The current valuation score of Applied Therapeutics Inc is 8.00, ranking 69 out of 393 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.03, which is -66.52% below the recent high of -0.34 and -600.49% above the recent low of -7.21.

Score

Industry at a Glance

Previous score

8.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 174/393

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-02

The current earnings forecast score of Applied Therapeutics Inc is 6.00, ranking 340 out of 393 in the Biotechnology & Medical Research industry. The average price target is 2.00, with a high of 2.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-02

The current price momentum score of Applied Therapeutics Inc is 4.11, ranking 353 out of 393 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.11 and the support level at 0.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.70

Change

0.41

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.019

Neutral

RSI(14)

35.575

Neutral

STOCH(KDJ)(9,3,3)

55.497

Buy

ATR(14)

0.008

High Vlolatility

CCI(14)

119.600

Buy

Williams %R

35.354

Buy

TRIX(12,20)

-1.820

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

0.097

Buy

MA10

0.100

Buy

MA20

0.101

Buy

MA50

0.150

Sell

MA100

0.506

Sell

MA200

0.464

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-02

The latest institutional shareholding proportion is 88.73%, representing a quarter-over-quarter decrease of 6.16%. The largest institutional shareholder is The Vanguard, holding a total of 6.35M shares, representing 4.17% of shares outstanding, with 0.17% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Investment Management, Inc.

21.40M

+14.55%

Simplify Asset Management Inc

15.77M

Vestal Point Capital, LP

14.25M

+23.91%

Knoll Capital Management, LLC

7.80M

The Vanguard Group, Inc.

Star Investors

5.10M

+7.79%

Propel Bio Management, LLC

6.02M

Shendelman (Shoshana)

4.72M

-10.72%

BlackRock Institutional Trust Company, N.A.

3.78M

-24.96%

PNC Investments LLC

2.90M

Risk Assessment

Currency: USD Updated: 2026-02-02

Applied Therapeutics Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.